<DOC>
	<DOCNO>NCT02713061</DOCNO>
	<brief_summary>This clinical trial Phase 2 study single subcutaneous injection TAK-850 22 day healthy Japanese adult .</brief_summary>
	<brief_title>A Phase 2 Study Subcutaneous Injection TAK-850 Healthy Adult Participants</brief_title>
	<detailed_description>The primary objective study evaluate safety immunogenicity single subcutaneous injection TAK-850 22 day healthy Japanese adult .</detailed_description>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant sign date write , informed consent form prior initiation study procedure . 3 . The participant healthy Japanese adult male female . 4 . The participant age 20 49 year , inclusive , time informed consent . 5 . The participant body mass index ( BMI ) 18.5 25.0 kg/m^2 , inclusive , time eligibility evaluation . 6 . If participant female childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study . 1 . The participant receive investigational compound within 4 month prior initial injection study vaccine . 2 . The participant vaccinate seasonal influenza vaccine within 6 month prior initial injection study vaccine . 3 . The participant history influenza infection within 6 month prior initial injection study vaccine 4 . The participant vaccinate TAK850 ( trivalent ) . 5 . The participant study site employee , immediate family member employee , dependent relationship study site employee involve conduct study ( e.g. , spouse , parent , child , sibling ) , may consent duress . 6 . The participant uncontrolled , clinically significant manifestation neurological , cardiovascular , pulmonary , hepatic , renal , metabolic , gastrointestinal , urologic , endocrine disorder , may impact ability participant participate potentially confound study result . 7 . The participant oral temperature ≥37.5°C prior initial injection study vaccine Day 1 . 8 . The participant medically diagnose suspect immune deficient condition . 9 . The participant immune compromise condition disease , currently undergo form treatment undergoing form treatment expect influence immune response within 30 day prior initial injection study vaccine . Such treatment include , limited , systemic high dose inhale corticosteroid ( &gt; 800 μg/day beclomethasone dipropionate equivalent ; use inhale nasal steroid exceed level permit ) , radiation treatment immunosuppressive cytotoxic drug . 10 . The participant receive antipyretic within 4 hour prior initial injection study vaccine . 11 . The participant history Guillain Barré Syndrome , demyelinate disorder ( include acute disseminate encephalomyelitis [ ADEM ] multiple sclerosis ) convulsion . 12 . The participant functional surgical asplenia . 13 . The participant rash , dermatologic condition tattoo may interfere evaluation injection site reaction determine Investigator . 14 . The participant history , infect Hepatitis B Virus ( HBsAgs ) , Hepatitis C Virus ( HCV ) Human Immunodeficiency Virus ( HIV ) . 15 . The participant know hypersensitivity component TAK850 . 16 . The participant history severe allergic reaction anaphylaxis . 17 . The participant history drug abuse ( define illicit drug use ) history alcohol abuse within 1 year prior initial injection study vaccine unwilling agree abstain alcohol drug throughout study . 18 . The participant receive blood product ( e.g . blood transfusion immunoglobulin ) within 90 day prior initial injection study vaccine . 19 . The participant receive live vaccine within 4 week ( 28 day ) inactivate vaccine within 2 week ( 14 day ) prior initial injection study vaccine . 20 . If female , participant pregnant lactate intend become pregnant signing informed consent , , within 1 month participate study ; intend donate ova time period . 21 . The participant donate whole blood ≥200 mL within 4 week ( 28 day ) , ≥400 mL within 12 week ( 84 day ) , ≥800 mL within 52 week ( 364 day ) , blood component within 2 week ( 14 day ) prior initial injection study vaccine . 22 . The participant abnormal laboratory value suggest clinically significant underlying disease assessment prior initial injection study vaccine , participant follow lab abnormality : alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) 3 time upper limit normal . 23 . In opinion investigator subinvestigator , participant unlikely comply protocol requirement consider ineligible reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>